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Abstract
Human social interaction is essential in daily life and crucial for a promising life, especially in people who suffer
from disease. Theory of Mind (ToM) is fundamental in social interaction and is described as the ability to impute the
mental states of others in social situations. Studies have proposed that a complex neuroanatomical network that
includes the frontal cortex mediates ToM. The primary neuropathology of Parkinson’s disease (PD) involves the
frontal-striatal system; therefore, patients with PD are expected to exhibit deficits in ToM. In this review, we
summarize the current research with a particular focus on the patterns of impaired ToM, potential mediators of
ToM, and the impact of ToM deficits on clinical disability in PD. Further studies to investigate the progression of
ToM and its relationship with dementia in subjects in PD are needed.
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Parkinson’s disease (PD) is a progressive neurodegene-
rative disorder pathologically characterized by the select-
ive loss of dopaminergic neurons in the substantia nigra.
Clinical manifestations include resting tremors, rigidity,
bradykinesia, and postural instability. Besides motor im-
pairment, dopamine depletion can also affect cognitive
and affective behavior [1]. Indeed, there is some evidence
to suggest that PD can develop years before the hallmark
of motor features [2]. Increasing evidence shows that pa-
tients with PD have non-motor symptoms, such as mild
cognitive impairment [3-12], dementia [13,14], and olfac-
tory dysfunction [15]. Of note, it has been suggested that
Theory of Mind (ToM), a concept within social cognitive
neuroscience that refers to the ability to attribute mental
state to oneself and others, is impaired in PD patients.
In fact, it has been demonstrated that some PD patients
possess social interaction impairment, such as being un-
able to detect or understand a caregiver’s emotion and
making inappropriate responses in a social situation. Fur-
thermore, our latest study provided first direct evidence
in Taiwanese population that non-demented PD patients
exhibit ToM dysfunction early in the disease process.
Hereby, we review the literature regarding the evidence
for ToM impairment and its impact in patients with PD;
the potential mediators related to ToM deficit.
Introduction
ToM is a complex neuropsychological concept that re-
fers to the ability to infer another’s thoughts, intentions,
or emotions to oneself. The ability to interact effectively
in a social situation is a necessary skill for successful
communication. A key component of ToM is the ability
to recognize the mental state of others. Premack and
Woodruff first coined the term “ToM” in a paper re-
porting on the mental states of chimpanzees [16]. Since
then, the ToM construct has been employed in many
human studies, especially those investigating psychiatric
disorders [17] and development disorders, such as autis-
tic spectrum disorders [18].
Whether or not ToM abilities improve or deteriorate
with age has also received attention. Given the well-
documented age-related functional decline of the frontal
lobes, an area of the brain implicated in ToM, it seems
logical that ToM abilities should also deteriorate. How-
ever, related research findings have been controversial. For
example, some scholars have suggested that performances
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on ToM tests declines significantly in people older than
55 y/o [19-23]. In contrast, other studies reported that eld-
erly individuals demonstrate preserved or superior ToM
abilities due to their well-seasoned life [24,25]. The idea
that an age-related decline in social understanding has
been proposed to be partially mediated by declining fluid
intelligence [26].
From normal ageing, research migrated to explo-
ring ToM in neurodegenerative disease, such as fronto-
temporal dementia [27], Alzheimer’s dementia [28,29],
and various basal ganglia disorders, including PD [30].
Given the importance of ToM in social communication
and life of quality in PD, we reviewed the status of the
research in ToM including the clinical manifestation of
cognition, health-related quality of life, effect of pharma-
cological and surgical therapy and the relationship of
ToM with non-motor symptoms of PD. The future di-
rection is also discussed at the end particularly on the
progression of ToM and dementia in PD.
The search strategy and the selection criteria
A comprehensive review of the literature was conducted
through PubMed and PsychINFO databases using the
following keywords: “Parkinson’s disease” and “Theory of
mind.” A literature search was undertaken for articles
published between January 2000 and December 2012.
The studies considered eligible were empirical studies
written in English and published in peer-reviewed jour-
nals. The search retrieved 17 original researches and
abstracts were further scrutinized to include only those
reports that through the study filter. The study inclusion
criteria were: (1) studies provide the quantitative ToM
data and focused in patients with PD and (2) comparison
of PD with healthy controls (HCs). Exclusion criteria
were: (1) the study topic is not ToM; and (2) studies fo-
cused on ToM in other population and with no relevant
data about ToM in PD. Finally, 13 articles [31-43] were
included in this review.
ToM dysfunction is common in PD
Few studies focusing on ToM and PD were carried out
at the beginning of the 21st century. The first study,
conducted by Saltzman et al. [31], compared the per-
formance of 11 non-demented PD patients [age: 71 years
old, Hoehn and Yahr stage, H&Y: 2.5, MMSE >26] with
8 age-matched HCs [31]. They demonstrated that PD
patients performed worse in false-belief stories and dur-
ing a spy model task; specifically, PD patients were less
able to make correct predictions based on inferences re-
garding a story-character’s belief, and they had more dif-
ficulty planning a course of action that would deceive
another person. Another study, by Mengelberg and col-
leagues (2003), reported that non-demented PD patients
demonstrated deficits in false beliefs, short-passage tasks,
and first-order story tasks, while their performance of
second-order story tasks was comparable to controls. Not-
ably, the authors found more pronounced ToM deficits in
the PD group with higher depression scores, and thus sug-
gested that depression impacts on ToM processing [32].
Over the past 6 years, studies have increasingly begun
to explore ToM ability in non-demented PD patients.
Taken together, the findings of these studies suggest that
ToM deficits occur during the pathological course of PD
and can represent additional non-motor symptoms. It
is believed that ToM has 2 subcomponents: cognitive
(”cold”) and affective (“hot”) [44]. Cognitive ToM refers
to the ability to make inferences about another’s cogni-
tive state, such as their intentions and motivations, while
affective ToM refers to the ability to recognize another’s
affective state, such as their feelings and emotions [45].
Some psychological tests, such as the Faux Pas Recogni-
tion task (FPR) and the Reading the Mind in the Eyes
test (REMT), were developed to measure ToM ability.
The FPR is a verbal ToM task, which reflects an individ-
ual’s ability to detect and attribute inappropriate behav-
ior in a social situation. The latter is a visual ToM task
that requires individuals to recognize or describe feel-
ings. An example question would be, “which of the fol-
lowing adjectives best describes the eye region shown:
excited, relieved, shy, or despondent”.
Bodden et al. examined affective ToM in 21 PD pa-
tients (age: 63.7, duration: 5.1 years, H&Y: 2.5, MMSE: 29)
and 21 HCs using REMT; compared to the control sub-
jects, PD patients scored lower on the REMT. Other re-
searchers found similar results and suggested that PD
patients could not accurately detect the feelings of another
person by simply looking at their eye region, even in the
initial [41] and early stages [39,41] of the disease. How-
ever, this finding could not be replicated by other re-
searchers [33,35,37,38], who instead reported that PD
patients may have preserved affective ToM performances
in the early stage of the disease [33,35,37,38].
These controversial results might be due to methodo-
logical differences employed; for example, the REMT
version used in the study by Roca et al. is an abbreviated
version in which 15 stimuli were used instead of the
usual 36, and the patients were asked to choose between
2 instead of 4 adjectives. Furthermore, the sample size in
the studies were quite small (n= 21 vs. 17) [33,35]. The
patients selected in the studies by Peron et al. [35,37]
were relatively young (average age: 56 and 53 years old).
Pondering the disease duration (10.2 vs. 10.5 years),
these patients are considered to be young onset Parkin-
sonism rather than late onset idiopathic PD.
Researchers have found that PD patients have im-
paired cognitive ToM. This is identified using various
tasks, such as the first-order false-belief story [31,32],
the second-order false-belief story [34,36], and the
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cognitive components of the FPR test [35,38] and the Yoni
test [36]. Many studies used FPR to assess cognitive ToM;
they found that PD patients have more difficulties de-
tecting the faux pas in a social situation and have declined
ability in recognizing the reason why a person in the story
made an inappropriate remark [35,38]. Roca and col-
leagues (2010) compared 36 early stage PD patients [16
medicated (age: 63.4, duration: 1.69 years, H&Y: 1.42,
MMSE: 29) and 20 drug free (age: 63.5, duration: 1.23
years, H&Y: 1.33, MMSE: 28.26)] and 35 HCs [38]; they
found cognitive ToM impairment in all patients regardless
of the presence or absence of dopamine replacement ther-
apy (DRT). Nevertheless, Peron et al. [35] reported that
only advanced PD patients [n= 27, age: 56.6 years old, dur-
ation: 10.2 years, H&Y: 1.3(on state) and 2.5(off), MDRS:
139.1] performed poorly on the intention attribution ques-
tion of the FPR. Moreover, Roca et al. [41] and Yu et al.
[43] suggested that not all early non-demented PD pa-
tients have impaired cognitive ToM. Both their studies
revealed that PD patients performed similarly to their
intelligence-matched HCs; in this case, intelligence was
measured by the verbal intelligence quotient (VIQ), and
the Raven’s Colored Progressive Matrices (RCPM). Re-
cently, Costa et al. [40] found that only patients with ex-
ecutive dysfunction have impaired cognitive ToM. Thus,
possible confounders, such as intelligence, executive func-
tion, and the heterogeneity of PD should be taken into ac-
count in future studies.
How ToM affect PD patients in daily living?
Studies have explored the impact of cognitive and affec-
tive ToM dysfunction on real life especially the quality
of life (QoL) [36,42]. Both studies used the PD question-
naire (PDQ-39) to measure the health-related QoL.
Bodden et al. [30] first found a significant correlation be-
tween total PDQ-39 score and measures of affective but
not cognitive ToM among patients with advanced stage
PD (H&Y: 2.5, range: I to III). Subsequently, Santangelo
and colleagues (2012) excluded depressed PD patients
and included early stage patients (H&Y: 1.5, range: I
to II) in order to explore this issue, and their results
showed that cognitive ToM was associated with 2 do-
mains, social support and cognitive deficits subscales, of
PDQ-39. Therefore, it was suggested that defects in the
cognitive aspect of ToM might have a more negative
impact on QoL compared to the affective component.
Taken together, these findings imply that ToM plays an
important role in daily living and affects QoL. However,
more research is still needed to explore the impact of
ToM on real life and social interactions.
What factors affecting ToM in PD ?
The literature to date suggests that the degree of ToM
alteration may vary in PD patients, depending on many
factors in disease course, including the clinical characteris-
tics, non-motor symptoms, and clinical management.
ToM descending as the disease progression
Summarizing all of the literature cited in this review, the
majority of studies report that PD patients in the early
stages of the disease progression may have preserved
affective ToM performances [33,35,37,38], even 10 years
after disease onset [35], with mild difficulties sometimes
emerging after 5 years [39]. However, impairment of cog-
nitive component in the ToM could be observed in both
the early [35,38,42] and moderate stage [31,32,34-36] of
the disease. It is believed that different areas of the frontal
cortices may be responsible for differential ToM pro-
cesses. There is some evidence to suggest that the ven-
tromedial prefrontal regions are crucial for processing
affective ToM [46,47], while the dorsolateral prefrontal
ones have been implicated in cognitive ToM [48,49]. Re-
cently, it has been revealed that cognitive and affective
subcomponents of ToM are linked to different fron-
tostriatal circuitries [30], which are known to be affected
by PD [50].
Here, we figured the current model of ToM processing
in PD (Figure 1). Affective ToM is believed to be pre-
dominately mediated by the orbital frontostriatal (OFS)
circuit, while cognitive ToM might additionally be rela-
ted to the dorsolateral frontostriatal (DLFS) loop [30,51].
During the early stages of PD, dopamine is mostly de-
pleted from the dorsolateral head of the caudate nucleus,
an area involved in the DLFS circuit, whereas the pro-
cesses based on the OFS circuit are almost completely
preserved. As PD progresses towards the advanced stage,
in which the prefrontal cortex is directly affected by the
neuropathology of PD, dopamine depletion within the
striatum also affects the OFS circuit, thus impairing re-
lated functions.
Figure 1 The model of ToM processing in PD. Blue: Dorsolateral
prefrontal cortex, Red: Orbitofrontal cortex.
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The role played by other non-motor symptoms in ToM
processing
Several studies have showed that neuropsychological
function, especially the frontal-related function, may be
a potential factor related to ToM. With regard to neu-
ropsychiatric symptoms, Mengelberg and Siegert (2003)
first mentioned that emotion disturbance might influence
ToM processing in PD; thus, the following researchers ex-
cluded PD patients with neuropsychiatric symptoms in
their studies. Recently, Santangelo and colleagues (2012)
investigated the relationship between neuropsychiatric
symptoms and ToM. They found that affective ToM
dysfunction is related to severity of apathy, as assessed by
the Apathy Evaluation Scale, and behavioral disturbances,
as assessed by the frontal behavioral inventory. The find-
ings of this study highlight the need for future research to
investigate the contribution of ToM to behavioral distur-
bances, such as paranoia and delusions, which are com-
mon in dementia.
Regarding the cognitive function, most studies have fo-
cused on executive function (EFs), which traditionally is
closely related to the frontal lobe and vulnerable cogni-
tive function in PD. Until now, the relationship between
EFs and ToM remained subject to debate. Some scholars
have demonstrated double dissociations between ToM
and EFs by controlling for EFs in their results [28,52-54];
while others have claimed that ToM is dependent upon
EFs [55-57]. Although controversial results exist, based
on correlation analysis, studies suggest that ToM ability
is related to EFs, such as mental shifting [42,43], concept
formation [43], reasoning [36], and inhibition abilities
[35]. Recently, Costa et al., [40] directly compared PD
patients with and without intact EFs and found that PD
patients with intact EFs have reduced ability to perform
ToM tasks. This association can be explained by the role
played by EFs, which are capable of compensating for
the deficits of ToM. Therefore, PD patients might gene-
rate advanced ToM by utilizing their EFs. EFs is a com-
plex construct that includes people’s abilities to plan,
manage, organize information, initiate and inhibit behav-
iors, and think abstractly and flexibly. Hence, future
work should investigate this function in a more compre-
hensive manner to determine the specific role of EF, es-
pecially with regard to the roles of inhibitory control
and working memory in the emergence and expression
of ToM in social situation.
The majority of participants in studies cited here were
non-demented PD patients. In these studies, the deficits
precede the development of dementia as defined by the
MMSE or MDRS, which have less sensitivity to detect
the PDD [7,58]. It has been suggested that a specturm
may exist from intact mental status to dementia. Indeed,
the transitional state, social function is a key point that
differeniates dementia from mild cognitive impairment
(MCI) [59,60]. So far, no empirical research has investi-
gated this related issue. With regard to the other disease
of the spectrum of Lewy body disease, Dementia with
Lewy bodies (DLB), by the progression of pathology in
Lewy body deposition or tau protein, the frontal lobe re-
gions implicated in ToM are affected by these abnormal
inclusion bodies [61]. Thus, ToM could be regarded as
the same pathological degenerative component that pre-
dicts the presence of dementia in PD. Much remains to
be done, studies should be undertaken to determine
whether ToM ability is altered in PD patients with MCI
or dementia in the hope of identifying whether ToM is a
decisive factor in the development of PDD.
The influence of pharmacological therapy and Deep Brain
Stimulation (DBS) in ToM processing
Even if it is acknowledged that the dopaminergic system
is involved in areas critical for intact ToM, the exact re-
lationship between dopamine and ToM has not yet been
fully established [35,38]. Peron et al. [35] explored the
involvement of the dopaminergic pathways in ToM by
comparing ToM performances of early stage PD patients
with and without DRT; they found no difference bet-
ween medicated and unmedicated PD patients and sug-
gested that dopaminergic pathways are not involved in
ToM. Later, Roca et al. [38] administered ToM tasks to
both medicated and de novo PD patients and also found
no significant differences between the 2 groups; in ad-
dition, no significant correlations were revealed between
ToM performance and the levodopa equivalent daily
dose within the medicated group. It is difficult to draw a
conclusion from these preliminary data because of meth-
odological limitations, such as the learning effect of
tasks, the small sample size, and the indirect testing of
the dopaminergic pathways. These findings may also
represent that ToM deficits not be attributed to dopa-
minergic depletion alone, other deficits of neurotrans-
mitters, such as serotonin or norepinephrine might also
influence the ToM processing.
DBS is a surgical treatment that inactivates parts
of the brain that cause PD. It has provided remarkable
therapeutic benefits for otherwise treatment-resistant
movement disorders. Only Peron and colleagues (2010)
investigated the effect of DBS in the subthalamic nucleus
(STN) on ToM of PD patients [37]. They conducted
18FDG-PET scans in 13 PD patients [age: 53.3 years old,
duration: 10.5 years, H&Y: 1.9 (pre-DBS) and 1.2 (post-
DBS), MDRS: 141.4 (pre-DBS) and 141.1 (post-DBS),
levodopa dosage: 1081.1 (pre-DBS) and 625.8 (post-DBS)]
in pre- and post-STN DBS conditions and correlated
changes in their glucose metabolism with modified perfor-
mances on the REMT. Regarding the affective ToM, the
authors found postoperative PD performances were worse
than HCs and preoperative PD performances, whereas
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there was no difference between preoperative PD and
HCs performances. The authors suggested that STN DBS
impairs ToM because of the overlap between the limbic
system, which is modulated by STN DBS in PD, and the
brain network that mediates ToM. Yet, further research is
needed to explore the influence of DBS in ToM by em-
ploying an exhaustive task, which covers both cognitive
and affective components of ToM.
Conclusion and future directions
The conclusions of our review are as such: (1) ToM de-
ficits can be detected in PD patients without dementia
and even at the time of PD diagnosis, (2) ToM abilities
are associated with reduced health-related QoL, (3) clini-
cal and other non-motor symptoms are associated with
ToM processing in PD patients.
The aforementioned preliminary research data sket-
ches out the nature of ToM in PD. About one-third of
PD patients develop dementia during the course of the
disease and the presence of dementia impacts greatly on
patients and caregivers. To our knowledge, no studies
have investigated whether ToM is a biomarker of PDD.
Further studies are needed to investigate whether ToM
deficits in PD are linear, whether different subcompo-
nents deficits have a different evolution, and the prog-
nostic utility of ToM in the development of dementia.
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